Cilostazol promotes mitochondrial biogenesis in human umbilical vein endothelial cells through activating the expression of PGC-1α

Biochemical and Biophysical Research Communications

Volumn 433, Issue 1, 2013, Pages 52-57

  Zuo, Luning ^a,b   Li, Qiang ^b   Sun, Bei ^b   Xu, Zhiying ^b   Ge, Zhiming ^c  

^a SHANDONG UNIVERSITY   (China)

^b YANTAISHAN HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

CAMP response element binding protein (CREB); Cilostazol; Mitochondrial biogenesis; Mitochondrial transcription factor A (TFAM); Peroxisome proliferator activator receptor gamma coactivator 1 (PGC 1 )

Indexed keywords

CELL NUCLEUS DNA; CILOSTAZOL; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOCHROME B; MESSENGER RNA; MITOCHONDRIAL DNA; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BIOGENESIS; DOWN REGULATION; HUMAN; HUMAN CELL; INCUBATION TEMPERATURE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL;

BASE SEQUENCE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA, MITOCHONDRIAL; GENE KNOCKDOWN TECHNIQUES; HEAT-SHOCK PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERMITTENT CLAUDICATION; ISOQUINOLINES; MITOCHONDRIAL TURNOVER; PHOSPHODIESTERASE 3 INHIBITORS; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SULFONAMIDES; TETRAZOLES; TRANSCRIPTION FACTORS;

EID: 84875805691     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.02.068     Document Type: Article

References (24)

1. Davidson S.M., Duchen M.R. Endothelial mitochondria: contributing to vascular function and disease. Circ. Res. 2007, 100:1128-1141.
2. Wu Z., Puigserver P., Andersson U., et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999, 98:115-124.
3. Addabbo F., Ratliff B., Park H.C., et al. The Krebs cycle and mitochondrial mass are early victims of endothelial dysfunction: proteomic approach. Am. J. Pathol. 2009, 174:34-43.
4. Kukidome D., Nishikawa T., Sonoda K., et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006, 55:120-127.
5. Sudo T., Tachibana K., Toga K., et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem. Pharmacol. 2000, 59:347-356.
6. Choi J.M., Shin H.K., Kim K.Y., et al. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J. Pharmacol. Exp. Ther. 2002, 300:787-793.
7. Lee J.H., Park S.Y., Shin Y.W., et al. Neuroprotection by cilostazol, aphosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res. 2006, 1082:182-191.
8. Lim J.H., Woo J.S., Shin Y.W. Cilostazol protects endothelial cells against lipopolysaccharide-induced apoptosis through ERK1/2- and P38 MAPK-dependent pathways. Korean J. Intern. Med. 2009, 24:113-122.
9. He Y., Chang G., Zhan S., et al. Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cells. Biochem. Biophys. Res. Commun. 2008, 370:489-494.
10. Zhou F., Zhang L., Gong K., et al. LEF-1 activates the transcription of E2F1. Biochem. Biophys. Res. Commun. 2008, 365:149-153.
11. Sheng B., Niu Y., Zhou H., et al. The mitochondrial function was impaired in APP knockout mouse embryo fibroblast cells. Chin. Sci. Bull. 2009, 54:1725-1731.
12. Kimura Y., Tani T., Kanbe T., et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneinmittelforschung 1985, 35:1144-1149.
13. Lonard D.M., O'Malley B.W. The expanding cosmos of nuclear receptor coactivators. Cell 2006, 125:411-414.
14. Kanlop N., Chattipakorn S., Chattipakorn N. Effects of cilostazol in the heart. J. Cardiovasc. Med. (Hagerstown) 2011, 12:88-95.
15. Yu E., Mercer J., Bennett M. Mitochondria in vascular disease. Cardiovasc. Res. 2012, 95:173-182.
16. Sheng B., Wang X., Su B., et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J. Neurochem. 2012, 120:419-429.
17. Dankel S.N., Hoang T., Flågeng M.H., et al. CAMP-mediated regulation of HNF-4α depends on the level of coactivator PGC-1α. Biochim. Biophys. Acta 2010, 1803:1013-1019.
18. Aliev G., Li Y., Palacios H.H., et al. Oxidative stress induced mitochondrial DNA deletion as a hallmark for the drug development in the context of the cerebrovascular diseases. Recent Pat. Cardiovasc. Drug Discovery 2011, 6:222-241.
19. Sprague R.S., Bowles E.A., Achilleus D., et al. Erythrocytes as controllers of perfusion distribution in the microvasculature of skeletal muscle. Acta Physiol. 2011, 202:285-292.
20. Kim K.Y., Shin H.K., Choi J.M., et al. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J. Pharmacol. Exp. Ther. 2002, 300:709-715.
21. Carreira R.S., Lee P., Gottlieb R.A. Mitochondrial therapeutics for cardioprotection. Curr. Pharm. Des. 2011, 17:2017-2035.
22. Faerber G., Barreto-Perreia F., Schoepe M., et al. Induction of heart failure by minimally invasive aortic constriction in mice: reduced peroxisome proliferator-activated receptor γ coactivator levels and mitochondrial dysfunction. J. Thorac. Cardiovasc. Surg. 2011, 141:492-500.
23. Wenz T. PGC-1α activation as a therapeutic approach in mitochondrial disease. IUBMB Life 2009, 61:1051-1062.
24. Srivastava S., Diaz F., Iommarini L., et al. PGC-1alpha/beta induced expression partially compensates for respiratory chain defects in cells from patients with mitochondrial disorders. Hum. Mol. Genet. 2009, 18:1805-1812.